GleamWall
中文EN

BFRI Biofrontera Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1858685 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.8%
TTM net income YoY61.6%
TTM EPS YoY76.4%
Revenue 3-yr CAGR16.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-14.2%
Net margin-13.8%
FCF margin-17.2%
EBITDA margin-14.0%

Returns

ROE-988.4%
ROA-28.8%
ROIC (approx.)—
Asset turnover2.09x

Leverage & solvency

Liabilities / assets75.2%
Debt / equity0.00x
Current ratio1.18x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.25x
Accruals ratio7.1%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$41.70M$37.32M
R&D expense$3.72M$2.09M
SG&A expense$37.75M$33.79M
Operating income-$11.35M-$17.21M
Pretax income-$10.51M-$17.74M
Income tax$25,000$22,000
Net income-$10.54M-$17.76M
EBITDA-$11.21M-$16.79M
EPS (basic)-1.04-3.22
EPS (diluted)-1.04-3.22
Weighted avg. shares (diluted)10.17M5.52M
Balance sheet
Cash & equivalents$6.39M$5.91M
Receivables$7.29M—
Inventory$1.43M$6.65M
Current assets$18.08M$20.70M
PP&E, net$2.16M$80,000
Intangibles$2.65M$35,000
Total assets$28.56M$22.10M
Current liabilities$11.89M$12.02M
Total liabilities$18.08M$17.67M
Shareholders' equity$10.48M$4.43M
Shares outstanding11.65M8.87M
Cash flow statement
Operating cash flow-$13.36M-$10.27M
Capital expenditure$2,000$10,000
Free cash flow-$13.36M-$10.28M
Investing cash flow$3.00M-$3,000
Financing cash flow$10.85M$14.84M
Depreciation & amortization$138,000$421,000
Stock-based compensation$951,000$1.02M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.